A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Interventions: DRUG: BYL719|DRUG: Paclitaxel
Sponsor: Novartis Pharmaceuticals